HNWAG
RLAY icon

High Net Worth Advisory Group’s Relay Therapeutics RLAY Stock Holding History

High Net Worth Advisory Group’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-500
Closed -$11K – 680
2022
Q3 		$11K Buy
+500
New +$11K ﹤0.01% 529

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

High Net Worth Advisory Group's RLAY Position: Q4 2022 in Review

High Net Worth Advisory Group sold out of Relay Therapeutics (RLAY) in Q4 2022, closing a stake of 500 shares — an estimated $11K sold.

High Net Worth Advisory Group first reported a position in RLAY in Q3 2022 and held it in 1 quarter. The position peaked at $11K in Q3 2022. 165 funds tracked by Wall St. Rank hold RLAY as of Q4 2022.

  • High Net Worth Advisory Group reported no remaining Relay Therapeutics position as of Q4 2022 after selling out during the quarter.
  • High Net Worth Advisory Group sold 500 Relay Therapeutics shares in Q4 2022, an estimated $11K.
  • High Net Worth Advisory Group first reported a position in Relay Therapeutics in Q3 2022 and held it in 1 quarter.
  • High Net Worth Advisory Group's Relay Therapeutics position peaked at $11K in Q3 2022.
  • 165 funds tracked by Wall St. Rank held Relay Therapeutics as of Q4 2022.

Based on High Net Worth Advisory Group's 13F filing for Q4 2022, filed 14 Feb 2023.